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ABSTRACT
Background. Breast-conserving therapy (BCT) is an
accepted therapeutic option for most breast cancer patients.
However, mastectomy is still performed in 30–50% of
patients undergoing surgeries. There is increasing interest
in preservation of the nipple and/or areola in hopes of
achieving improved cosmetic and functional outcomes;
however, the oncologic safety of nipple–areolar complex
(NAC) preservation is a major concern. We sought to
identify the predictive factors for NAC involvement in
breast cancer patients.
Methods. We analyzed the rates and types of NAC
involvement by breast carcinoma, and its association with
other clinicopathologic features of the tumors in 787 con-
secutive therapeutic mastectomies performed at our
institution between 1997 and 2009.
Results. Among these, 75 cases (9.5%) demonstrated
NAC involvement. Only 21 (28%) of 75 of cases with
NAC involvement could be identiﬁed grossly by inspection
of the surgical specimen (seven of these had been clinically
identiﬁed). NAC involvement was most signiﬁcantly
associated with tumors located in all four quadrants
(P\0.0001), tumors[5 cm in size (P = 0.0014 for
invasive carcinoma and P = 0.0032 for in-situ carcinoma),
grade 3 tumors (P = 0.0192), tumors with higher nuclear
grades (P = 0.0184), and tumors with HER2 overexpres-
sion (P = 0.0137).
Conclusions. On the basis of our ﬁndings, we have
developed a mathematical model that is based on the extent
and location of the tumor, HER2 expression, and nuclear
grade that predicts the probability of NAC involvement by
breast cancer. This model may aid in preoperative planning
in selecting appropriate surgical procedures based on an
individual patient’s relative risk of NAC involvement.
After the results of the NSABP B-06 study were
reported, the National Institutes of Health released a con-
sensus statement on the ‘‘Treatment of Early-Stage Breast
Cancer’’ stating that ‘‘breast conservation treatment is an
appropriate method of primary therapy for the majority of
women with Stage I and II breast cancer and is preferable
because it provides survival equivalent to total mastectomy
and axillary dissection while preserving the breast’’.
1,2 As a
result, breast-conserving therapy (BCT) is an accepted
therapeutic option for most breast cancer patients.
3 How-
ever, mastectomy is still performed in 30–50% of patients
undergoing surgery for breast cancer, either because the
patient is not thought to be a candidate for BCT or because
of patient preference. Many women undergo immediate
reconstruction at the time of their mastectomy, and skin-
sparing mastectomy (SSM) is routinely performed in this
setting. SSM, which removes all breast tissue, the nipple–
areola complex (NAC), and biopsy scar if present, has been
proven to be oncologically safe compared to conventional
non-SSM.
4 There is increasing interest in preservation of
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DOI 10.1245/s10434-011-2107-3the nipple and/or areola in hopes of achieving improved
cosmetic and functional outcomes.
5–8 Studies have shown
that the rates of NAC involvement vary from 0 to 58%.
9–11
However, these early studies may not serve as a reliable
guide for current practice, as the indications for mastec-
tomy have shifted from being the only choice for all breast
cancer patients to being used primarily for larger and
multicentric tumors, tumors with multiple positive mar-
gins, or recurrent tumors. Clearly, NAC removal may not
be necessary for all patients undergoing mastectomy.
Nipple-sparing mastectomy (NSM) as a potential alterna-
tive to SSM may be suitable only for a small and ill-deﬁned
group of candidates who have small solitary and/or
peripheral tumors.
12–14 Because NSM does leave behind
possible occult nipple involvement by primary tumor and
ductal tissue that may become the origin for new cancer, its
oncologic safety remains controversial.
This current study utilized the therapeutic SSM speci-
mens from a large retrospective cohort of patients in which
the NAC were uniformly processed and entirely embedded
for microscopic examination. We intended to investigate
the frequency of occult NAC involvement in this unse-
lected population of patients in this postmammogram era;
the types of lesions that involve the NAC; and the clini-
copathologic factors most frequently associated with NAC
involvement. Finally, we sought to propose a model that
may predict NAC involvement with reasonable accuracy
on the basis of our current data.
METHODS
Seven hundred eighty-seven consecutive unselected ther-
apeutic mastectomies from the ﬁles of the Department of
Pathology at the University of Rochester Medical Center
between 1997 and 2009 were identiﬁed. These included 21
cases with clinically (n = 7) or grossly identiﬁed (n = 21,
including the seven clinically identiﬁed cases) NAC
involvement. All mastectomy specimens were inked and
sectioned from medial to lateral into no greater than 1-cm-
thick tissue sections and grossly examined. The nipples were
uniformly shaved, sectioned at 2–3-mm intervals vertically,
and submitted perpendicularly for microscopic examination,
and the areolas were shaved and submitted en face. The
identiﬁcation of tumor cells in these sections was considered
as NAC involvement. Clinical and pathologic factors
includingpatient age,tumor location(e.g.,upper inner,upper
outer,lowerinner,lowerouter,orcentralwithorwithoutother
quadrants; many tumors involved more than one quadrant),
tumor type (ductal carcinoma-in-situ [DCIS], invasive ductal
carcinoma [IDC], invasive lobular carcinoma [ILC], lobular
carcinoma-in-situ [LCIS], or any combination of the
above), multifocality (deﬁned as two or more tumor foci
present[1 cm apart from each other), tumor size (divided
into four subgroups:\1 cm, 1–2 cm, 2–5 cm, and,[5c m ) ,
histological grade (according to the modiﬁed Bloom-Rich-
ardson grading system), nuclear grade (using the 3-tier
grading system), expression of estrogen receptor (ER), pro-
gesterone receptor (PR), and HER2 (ER and PR recorded as
Allredscores,andHER2recordedaccordingtonewAmerican
Society of Clinical Oncology/College of American Patholo-
gists guidelines, which scores as a positive stain when[30%
of invasive tumor cells have uniform strong membrane
staining), and lymph node status (recorded as positive or
negative) were reviewed and recorded.
Statistical analysis was performed to compare tumors
with or without nipple involvement. Apart from the
descriptive analysis presented by percent of tumors with or
without nipple involvement in each subgroup, the P values
from Fisher’s exact test were provided as index to indicate
the difference between subgroups on the proportion of
cancers with nipple involvement. The logistic regression
was used to develop a model to predict the probability of
cancer with nipple involvement under different conditions.
RESULTS
Patient demographics and the clinicopathologic charac-
teristics of the 787 mastectomy specimens are listed in
Table 1. Among the 787 cancers treated with mastectomy,
488 were IDC, 197 were DCIS, 63 were ILC, 22 were
mixed IDC and ILC, 13 were LCIS, 3 were malignant or
borderline phyllodes tumors, and one was a myoﬁbrob-
lastic sarcoma. In 75 cases (9.5%), there was NAC
involvement by carcinoma demonstrated microscopically.
Three cases of intraductal papilloma in the NAC and three
cases with other benign lesions (neuroma, adenoma and
trachoma) identiﬁed in NAC were not included in the
statistical analysis. Among the 75 cases with microscopi-
cally identiﬁed NAC involvement, only 21 cases (28%)
were identiﬁed clinically and/or grossly (Table 2).
Mammary Paget disease was the most common nipple
lesion in our study with 25 cases (33%), followed by 17
DCIS (23%), 15 IDC (20%), 11 LCIS (15%), four lym-
phovascular invasion (5%), and three ILC (4%) (Table 2).
Less than a third of cases of Paget disease were identiﬁed
clinically, and about half of the cases of Paget disease were
identiﬁed grossly, which accounted for half of all grossly
identiﬁed NAC lesions. Paget disease was the only lesion
that was identiﬁed clinically.
NAC involvement was most signiﬁcantly associated
with tumor location (P\0.0001). Tumors that were
located in 1–3 quadrants were much less likely to have
NAC involvement (4–10%) compared to tumors that were
centrally located (21%) or located in all four quadrants
Predicting Nipple–Areolar Complex Involvement 1175(34%). Tumors[5 cm in size were more likely to have
nipple involvement for both in situ (18%, P = 0.0032) and
invasive carcinomas (20%, P = 0.0014) than smaller
tumors (6–10% for in situ tumors and 7–8% for invasive
tumors, respectively). NAC involvement was also signiﬁ-
cantly associated with high histological grade (P =
0.0192) and nuclear grade (P = 0.0184). HER2 positivity
was strongly associated with NAC involvement (7% in
HER2 negative vs. 18% in HER2 positive tumors,
P = 0.0137). Lymph node involvement was also associ-
ated with NAC involvement (8% in negative vs. 14% in
positive tumors, P = 0.0331). Other clinicopathologic
factors including patient age, tumor type, multifocality, and
expression levels of ER and PR were not associated with
NAC involvement (Table 3).
Among the factors that were associated with NAC
involvement, tumor location, tumor HER2 status and
nuclear grade are often known preoperatively with rea-
sonable accuracy (Table 4). We generated a predictive
table based on a mathematical model to predict the prob-
ability of NAC involvement by breast cancer using
these three factors (Table 5). The probability for NAC
involvement is lowest (1.7%) when the tumor is located in
one quadrant, has a low nuclear grade and is HER2 neg-
ative; and highest (66%) when the tumor is located in all
four quadrants, has a high nuclear grade and is HER2
positive.
DISCUSSION
Most studies regarding the rate of NAC involvement by
breast carcinomas are from the premammogram screening
era, and thus may not reﬂect the current rate of NAC
involvement. Also, the shift from mastectomy to breast
conservation surgery, variations in patient population and
in tissue processing for the NAC may also impact the
observed rates of NAC involvement. A small study in 1989
of 33 cases of mostly multicentric, incompletely resected
and recurrent tumors, tumors[5 cm or with retracted
nipple showed a rate of NAC involvement of 58%.
10 A
similar rate of 50% of NAC involvement was also observed
by Andersen and Pallesen in 1978.
15 Both studies exam-
ined multiple transverse or vertical sections from the
nipple. On the other hand, a study of 26 cases with tumors
that were at least 2.5 cm from the areola and nipple showed
no NAC involvement microscopically.
11 In the current
study, the rate of NAC involvement is 9.5%, which is
compatible with prior studies of 12–23% NAC involve-
ment.
9,16,17 Laronga et al. reported that 5.6% of their 326
cases showed involvement of the NAC, but they had
removed cases that had clinical NAC involvement.
18 Also,
many studies reported before routine mammographic
screening and the use of BCT would have included smaller
and peripheral tumors in their mastectomy series, which
would likely lower the rate of NAC involvement.
11,18
Sampling technique is another factor that affects the rate of
reported nipple involvement. The traditional one sagittal
section of the nipple is likely to underestimate occult NAC
involvement compared to the microscopic examination of
multiple coronal or vertical sections of the nipple that was
used in our study and in others.
10,15,19
Tumor size, tumor location, and lymph node status are
three pathologic factors consistently shown to be associ-
ated with NAC involvement.
18,20,21 This was conﬁrmed in
our study. We did not have information on the distance
between tumor and nipple in our study, though many
studies have shown that it is an important factor affecting
the rate of NAC involvement.
11,18,22 Lagios et al. con-
ﬁrmed this association with invasive carcinomas, but not
TABLE 1 Clinicopathologic features of breast cancer in the current
study
Characteristic Value
Total cases 787
Types of tumors in breast
DCIS 197
IDC 488
ILC 63
IDC ? ILC 22
LCIS 13
Phyllodes tumor 3
Myoﬁbroblastic sarcoma 1
Mean patient age, y 56.88
Mean tumor size (invasive) (cm) 2.3084
Mean tumor size (in situ) (cm) 2.8021
Positive lymph node/total cases 246/646 (30%)
Tumors in NAC 75/787 (9.53%)
TABLE 2 Nipple lesions observed clinically, grossly, and micro-
scopically
Lesion Clinical Gross Microscopic
Total no. 7 21 75
Mammary Paget disease 7 (100%) 12 (57%) 25 (33%)
DCIS 0 1 (4.5%) 17 (23%)
IDC 0 5 (24%) 15 (20%)
LCIS 0 2 (10%) 11 (15%)
Lymphatic involvement 0 1 (4.5%)
a 4 (5%)
ILC 0 0 3 (4%)
a In this case, the tumor was 3.8 cm, grossly abutting the NAC; thus,
it was grossly noted as NAC involvement. Under the microscope, the
only ﬁnding from the two sections (perpendicular sections of the
nipple and the shaved section of areolar) was lymphovascular
invasion
1176 J. Wang et al.with DCIS.
22 Routine gross measurement of the distance
from tumor mass to nipple is not always reliable, and this is
especially true in cases that involve DCIS, which often
present beyond grossly identiﬁable lesions.
HER2 overexpression in our study was predictive for
NAC involvement, with a P value of 0.0137. Brachtel et al.
also showed that HER2 overexpression is associated with
NAC involvement.
23 Among the 177 cases with HER2
information in their study, 43 cases had NAC involvement,
16 of 43 of which had HER2 overexpression, resulting in a
rate of 37%. In the current study, among the 43 cases with
NAC involvement that had HER2 testing, 14 had HER2
TABLE 3 Comparison of NAC-negative and NAC-positive cases of
breast cancer
Characteristic NAC
negative
(712 cases)
NAC
positive
(75 cases)
P value
Age, year (787 cases) 712 cases 75 cases 0.8532
\40 (77 cases) 92% 8%
40–60 (417 cases) 90% 10%
[60 (293 cases) 90% 10%
Tumor location (771 cases) 696 cases 75 cases \0.0001
1 quadrant (382 cases) 96% 4%
2 quadrants (200 cases) 92% 9%
3 quadrants (30 cases) 90% 10%
4 quadrants (35 cases) 66% 34%
Central (124 cases) 79% 21%
Tumor type (787 cases) 712 cases 75 cases 0.4574
DCIS (197 cases) 90% 10%
IDC (488 cases) 91% 9%
ILC (54 cases) 89% 11%
IDC ? ILC (31 cases) 81% 19%
LCIS (13 cases) 92% 8%
Phyllodes tumor (3 cases) 100% 0%
Myoﬁbroblastic SA (1 case) 100% 0%
Multifocality (784 cases) 708 cases 76 cases 0.1658
No (629 cases) 91% 9%
Yes (155 cases) 88% 12%
Size-invasive tumors
(769 cases)
701 cases 68 cases 0.0014
\1 cm (301 cases) 92% 8%
1t o\2 cm (161 cases) 93% 7%
2 to 5 cm (214 cases) 93% 7%
[5 cm (93 cases) 80% 20%
Size of in situ tumors
(741 cases)
672 cases 69 cases 0.0032
\1 cm (232 cases) 94% 6%
1t o\2 cm (125 cases) 90% 10%
2 to 5 cm (261 cases) 92% 8%
[5 cm (123 cases) 81% 18%
Histologic grade
(473 cases)
429 cases 44 cases 0.0192
1 (129 cases) 96% 4%
2 (181 cases) 91% 9%
3 (163 cases) 87% 14%
Nuclear grade (632 cases) 573 cases 59 cases 0.0184
1 (98 cases) 96% 4%
2 (290 cases) 92% 8%
3 (244 cases) 87% 13%
Estrogen receptor
(512 cases)
462 cases 50 cases 0.9334
Negative (131 cases) 89% 11%
Positive (381 cases) 91% 9%
TABLE 4 Logistic regression to predict NAC involvement by
tumors
a
Parameter Estimate Standard
error
Wald v
2 P[v
2
Intercept -4.0670 0.6599 37.9797 \0.0001
Two-quadrant
involvement
1.2319 0.5478 5.0574 0.0245
Three-quadrant
involvement
1.1669 1.1390 1.0494 0.3056
Four-quadrant
involvement
3.2843 0.6635 24.5053 \0.0001
Central location 2.2656 0.5148 19.3679 \0.0001
HER2 positive 0.7979 0.4398 3.2918 0.0696
Nuclear grade 2 0.1695 0.6163 0.0757 0.8732
Nuclear grade 3 0.0013 0.6208 1.1348 0.2867
a Intercept = log(P/(1 - P)) for a reference patient. The reference
patient is deﬁned as the patient having zero on all of the variables. In
our case, the reference patient is the patient with a tumor that has one
quadrant involvement, no central location, negative for HER2 over-
expression, and a nuclear grade of one. Thus, in our case,
-4.0670 = log(P/(1 - P)) where P = 1.68%. It means for a refer-
ence patient, her chance of NAC involvement is 1.68%. P indicates
the probability of the NAC involvement
TABLE 3 continued
Characteristic NAC
negative
(712 cases)
NAC
positive
(75 cases)
P value
Progesterone receptor
(511 cases)
461 cases 50 cases 0.2588
Negative (175 cases) 87% 13%
Positive (336 cases) 92% 8%
HER2 overexpression (466 cases) 423 cases 43 cases 0.0137
Equivocal (1 case) 100% 0%
Negative (387 cases) 93% 7%
Positive (78 cases) 82% 18%
Lymph node status (646 cases) 579 cases 67 cases 0.0331
Negative (399 cases) 366 (92%) 33 (8%)
Positive (247 cases) 213 (86%) 34 (14%)
Predicting Nipple–Areolar Complex Involvement 1177overexpression (33%). The association of HER2 positivity
with NAC involvement may be related to the presence of
mammary Paget disease, which accounts for one of three of
our NAC involvement cases. We have shown in a previous
study that HER2 overexpression is one of the critical fac-
tors in predicting mammary Paget disease, which was
excluded from the study of Brachtel et al.
23,24 Heregulin-a,
a HER-receptor family ligand and motility factor produced
by normal epidermal keratinocytes, may play a role in the
pathogenesis of Paget disease.
25 The binding of heregulin-
alpha to the HER2-receptor complex on Paget cells may
serve as a chemotactic signal and result in migration of
tumor cells into the overlying nipple epidermis.
We also observed that Paget disease, DCIS and IDC are
the most common types of lesions that involve NAC,
consistent with many prior studies.
10,16,26 A higher nuclear
grade tended to be associated with all types of NAC
involvement, with the exception of lobular carcinomas
(data not shown), consistent with prior studies.
22 Luttges
et al. have shown that multicentricity and multifocality
correlated with NAC involvement.
27 We did observe a
statistically signiﬁcant difference in NAC involvement
between tumors present in 1–3 quadrants and tumors
present in all 4 quadrants, but we did not conﬁrm mul-
tifocality to be associated with NAC involvement, which
was the observation by Brachtel et al.
23
Currently, SSM is being used in most centers, including
ours, which allows the removal of all breast tissue and the
NAC, but preserves most of the native skin enveloping the
breast.
4 Because NAC involvement is present in only a
small percentage of breast cancers, some believe that NSM,
which preserves the NAC and may provide better cosmeses
and functional results, may be an appropriate alternative
for many patients undergoing mastectomy with immediate
reconstruction.
5–7,27–29 Because most of the NAC
involvement occurs within the nipple and not the areola,
Simmons et al. suggested areolar-sparing mastectomy with
removal of nipple while preserving the areola as an alter-
native to NSM.
21 To exclude any patient with occult nipple
involvement in this setting, intraoperative pathologic
evaluation of retroareolar en-face margin or NAC core
biopsy have been used in many centers.
13,30 However,
these techniques are not perfect; and there are still both
false positive and false negative cases associated with
them.
23,31 Intraoperative retroareolar en-face margin
assessment may be used to detect occult tumor involve-
ment in patients undergoing NSM.
14,23 Nipple needle core
biopsies have also been performed to evaluate possible
occult NAC involvement intraoperatively.
13
The ability to accurately predict NAC involvement
preoperatively can help clinicians and patients to choose
the proper surgical procedure. Vyas et al. found that tumors
2.5 cm away from the NAC are predictive for no nipple
involvement.
32 Recurrence rate in the NAC was found to
be low in patients who had early stage tumors and whose
tumor was more than the 2 cm away from the NAC.
14 We
previously proposed that immunopathologic patterns
strongly associated with mammary Paget disease depend
upon the underlying tumor type (ER negative, PR negative,
and HER2-positive for DCIS and HER2-positive for
IDC).
24 Schecter et al. proposed a predictive model for
NAC involvement with 92% sensitivity and 77% speci-
ﬁcity based on mammographic distance between tumor and
nipple, tumor size, and pathologic staging in a small study
of 31 cases.
33 Rusby et al. have reported a similar pre-
dictive model on the basis of a study of 130 patients.
34
TABLE 5 Probability of NAC involvement by logistic regression
model
a
Tumor location HER2 Nuclear G Probability (%)
1 quadrant - 1 1.7
1 quadrant - 2 2.0
1 quadrant - 3 3.2
1 quadrant ? 1N D
1 quadrant ? 2 4.3
1 quadrant ? 3 6.9
2 quadrants - 1 5.6
2 quadrants - 2 6.5
2 quadrants - 3 10.2
2 quadrants ? 1 11.5
2 quadrants ? 2 13.4
2 quadrants ? 3 20.2
3 quadrants - 1N D
3 quadrants - 2 6.1
3 quadrants - 3 9.6
3 quadrants ? 1N D
3 quadrants ? 2 12.6
3 quadrants ? 3 19.1
4 quadrants - 1 31.4
4 quadrants - 2 35.1
4 quadrants - 3 47.0
4 quadrants ? 1N D
4 quadrants ? 2N D
4 quadrants ? 3 66.3
Central - 1 14.2
Central - 2 16.4
Central - 3 24.2
Central ? 1N D
Central ? 2 30.3
Central ? 3 41.5
ND no data (the data set does not include this kind of cancer, so its
probability cannot be predicted)
a 1xbeta = (-4.0670 ? location ? HER2 ? nuclear grade); proba-
bility of NAC involvement = [exp(xbeta)/(1 ? exp(xbeta))]
1178 J. Wang et al.Gulben et al. recently reported that tumor location, positive
lymph nodes, and lymphatic vascular invasion were the
most important risk factors; and patients with two or three
risk factors had a 50% rate of NAC involvement versus
only 8% in patients with one or no risk factors.
35
In this study, we have shown that NAC involvement is
not a rare event, and is strongly associated with tumor
location, tumor size, histological grade, and HER2 over-
expression. The predictive model we propose here aims to
provide some guidance for patients and clinicians in pre-
surgical planning, in conjunction with intraoperative
evaluation of retroareolar en-face margin, to selective
patients who are suitable for NSM.
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